9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Renal Dysfunction in Patients With Direct Infiltration by B-Cell Lymphoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          B-cell lymphoproliferative disorders with renal involvement are relatively frequent, but remain poorly described. A kidney biopsy is usually required to detect the renal lesions that are often missed using other diagnostic tools.

          Methods

          We retrospectively identified 34 patients with renal lymphoma diagnosed by percutaneous kidney biopsy (PKB) at Rennes University Hospital and its affiliated hospital centers between January 1, 2004, and May 1, 2016. Clinical, biological, radiological, and histological characteristics were collected at biopsy time.

          Results

          The included patients had Waldenström macroglobulinemia ( n = 12; 35.3%), chronic lymphocytic leukemia/lymphocytic lymphoma ( n = 10; 29.5%), high-grade B-cell lymphoma ( n = 6; 17.6%), and low-grade B-cell lymphoma ( n = 6; 17.6%). The median follow-up was 29 months. Renal involvement led to renal function impairment in 29 patients (85.3%), among whom 20 had acute kidney injury (70%), and to nephrotic syndrome in 4 patients (11.8%). Only 13 patients (38.2%) presented morphological kidney anomalies among whom 5 showed bilateral infiltration. Histologically, interstitial infiltrate (97.1%) was the most common kidney lesion, and 9 patients (26.5%) had specific lymphomatous intraglomerular lesions. After hematological treatment ( n = 29), a renal response was observed only in 8 patients (27.6%).

          Conclusion

          Renal involvement in the context of B-cell lymphoproliferative disorders is not uncommon. PKB is the best method to confirm this diagnosis. It should be performed early to rapidly initiate the hematological treatment to preserve kidney function.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: found

          KDIGO Clinical Practice Guidelines for Acute Kidney Injury

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

            The Ann Arbor classification for describing the stage of Hodgkin's disease at initial presentation has formed the basis upon which treatment is selected and has allowed comparison of results achieved by different investigators for almost two decades. A meeting was convened to review the classification and modify it in the light of experience gained in its use and new techniques for evaluating disease. It was concluded that the structure of the classification be maintained. It was particularly recommended: (1) that computed tomography (CT) be included as a technique for evaluating intrathoracic and infradiaphragmatic lymph nodes; (2) that the criteria for clinical involvement of the spleen and liver be modified to include evidence of focal defects with two imaging techniques and that abnormalities of liver function be ignored; (3) that the suffix 'X' to designate bulky disease (greater than 10 cm maximum dimension) be introduced; and (4) that a new category of response to therapy, unconfirmed/uncertain complete remission (CR[u]), be introduced to accommodate the difficulty of persistent radiological abnormalities of uncertain significance.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival

              Background Optimal chemotherapy with minimal toxicity is the main determinant of complete remission in patients with newly diagnosed hematological malignancies. Acute organ dysfunctions may impair the patient’s ability to receive optimal chemotherapy. Design and Methods To compare 6-month complete remission rates in patients with and without acute kidney injury (AKI), we collected prospective data on 200 patients with newly diagnosed high-grade malignancies (non-Hodgkin lymphoma, 53.5%; acute myeloid leukemia, 29%; acute lymphoblastic leukemia, 11.5%; and Hodgkin disease, 6%). Results According to RIFLE criteria, 137 (68.5%) patients had AKI. Five causes of AKI accounted for 91.4% of cases: hypoperfusion, tumor lysis syndrome, tubular necrosis, nephrotoxic agents, and hemophagocytic lymphohistiocytosis. Half of the AKI patients received renal replacement therapy and 14.6% received suboptimal chemotherapy. AKI was associated with a lower 6-month complete remission rate (39.4% vs. 68.3%, P<0.01) and a higher mortality rate (47.4% vs. 30.2%, P<0.01) than patients without AKI. By multivariate analysis, independent determinants of 6-month complete remission were older age, poor performance status, number of organ dysfunctions, and AKI. Conclusion AKI is common in patients with newly diagnosed high-grade malignancies and is associated with lower complete remission rates and higher mortality.
                Bookmark

                Author and article information

                Contributors
                Journal
                Kidney Int Rep
                Kidney Int Rep
                Kidney International Reports
                Elsevier
                2468-0249
                12 February 2019
                May 2019
                12 February 2019
                : 4
                : 5
                : 688-697
                Affiliations
                [1 ]CHU de Rennes, Service de Néphrologie, Rennes, France
                [2 ]CHU de Rennes, Service d’Anatomo-cytopathologie, Rennes, France
                [3 ]CHU de Rennes, Service d’Hématologie, Rennes, France
                [4 ]CHU de Rennes, Service de Médecine Interne, Rennes, France
                [5 ]IRSET, Rennes, France
                Author notes
                [] Correspondence: Cécile Vigneau, CHU de Rennes, Service de Néphrologie, 2 Rue H Le Guilloux, Rennes, F-35033, France. Cecile.vigneau@ 123456chu-rennes.fr
                Article
                S2468-0249(19)30052-X
                10.1016/j.ekir.2019.02.008
                6506703
                31080924
                8ed1088a-608a-4df9-b1eb-369e7071e02c
                © 2019 International Society of Nephrology. Published by Elsevier Inc.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 21 November 2018
                : 28 January 2019
                : 4 February 2019
                Categories
                Clinical Research

                acute kidney injury,kidney biopsy,renal lymphoma
                acute kidney injury, kidney biopsy, renal lymphoma

                Comments

                Comment on this article